From the Journals

Albumin Therapy Tested in Septic Shock

Multicenter randomized study finds similar mortality and organ failure outcomes with albumin therapy and standard fluid care

Share

A multicenter randomized clinical trial in Germany, involving 440 adults with septic shock, investigated the efficacy of albumin replacement therapy compared to standard fluid management. Patients were given a loading dose of 20% albumin and monitored for 90 days. The study found no significant difference in mortality rates between the two groups, with 43% in the albumin group and 46% in the control group succumbing within this period. Although albumin therapy demonstrated safety, it did not enhance survival rates, underscoring the need for further research to explore potential benefits in specific patient subgroups.

Original Source(s)

Albumin Therapy Tested in Septic Shock

Multicenter randomized study finds similar mortality and organ failure outcomes with albumin therapy and standard fluid care

  • by Henry Thomas

  • March 4, 2026

  • 3 min

Related Content

Sepsis Antibiotic Timing Shows Physician Divide

Emergency department physicians differ in how quickly they initiate antibiotics for suspected sepsis.

Pneumonia Patterns Postpandemic

Pneumococcal and RSV RAD-CAP incidence increased as SARS-CoV-2 incidence declined, disproportionately affecting older adults.

Leukemia Case Prompts Broader Review

Researchers assess hematologic malignancies temporally associated with mRNA COVID-19 vaccination.